Oral selective estrogen receptor degraders in ER+/HER2- breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence.

amcenestrant (SAR439859) - Sanofi

giredestrant (RG6171) - Roche

Orserdu (elacestrant) - Menarini

Inluriyo (imlunestrant) - Eli Lilly

Veppanu (vepdegestrant) - Rigel Pharmaceuticals

Etcamah (camizestrant) - AstraZeneca

http://www.ncbi.nlm.nih.gov/pubmed/42755923

Bing Guan; Lulu Li; Ping He; Rong Zhou; Sijia Zhang; Yawen Chen

Sep 19, 2026